畸齿矫正学
发表于 2025-3-21 18:21:54
书目名称Clinical Trials In Parkinson‘s Disease影响因子(影响力)<br> http://impactfactor.cn/2024/if/?ISSN=BK0228259<br><br> <br><br>书目名称Clinical Trials In Parkinson‘s Disease影响因子(影响力)学科排名<br> http://impactfactor.cn/2024/ifr/?ISSN=BK0228259<br><br> <br><br>书目名称Clinical Trials In Parkinson‘s Disease网络公开度<br> http://impactfactor.cn/2024/at/?ISSN=BK0228259<br><br> <br><br>书目名称Clinical Trials In Parkinson‘s Disease网络公开度学科排名<br> http://impactfactor.cn/2024/atr/?ISSN=BK0228259<br><br> <br><br>书目名称Clinical Trials In Parkinson‘s Disease被引频次<br> http://impactfactor.cn/2024/tc/?ISSN=BK0228259<br><br> <br><br>书目名称Clinical Trials In Parkinson‘s Disease被引频次学科排名<br> http://impactfactor.cn/2024/tcr/?ISSN=BK0228259<br><br> <br><br>书目名称Clinical Trials In Parkinson‘s Disease年度引用<br> http://impactfactor.cn/2024/ii/?ISSN=BK0228259<br><br> <br><br>书目名称Clinical Trials In Parkinson‘s Disease年度引用学科排名<br> http://impactfactor.cn/2024/iir/?ISSN=BK0228259<br><br> <br><br>书目名称Clinical Trials In Parkinson‘s Disease读者反馈<br> http://impactfactor.cn/2024/5y/?ISSN=BK0228259<br><br> <br><br>书目名称Clinical Trials In Parkinson‘s Disease读者反馈学科排名<br> http://impactfactor.cn/2024/5yr/?ISSN=BK0228259<br><br> <br><br>
正论
发表于 2025-3-21 20:29:07
Assessment of Nonmotor Symptoms in Rodent Models of Parkinson’s Disease (PD) neuropathology and to develop new therapeutic strategies. The toxin-based rodent models of PD offer a valuable tool as they allow to mimic many of the features of the disease, particularly motor symptoms such as akinesia and bradykinesia. Interestingly, PD nonmotor symptoms, such as neuropsych
小争吵
发表于 2025-3-22 00:42:03
Genetic Models of Parkinson’s Disease The etiology of idiopathic PD, which represents most of the cases, is still unclear but seems to be multifactorial, associating environmental and/or genetic factors. The major limitation of “classical” toxin-based animal models of PD is that they do not replicate some characterizing features of the
多嘴
发表于 2025-3-22 08:14:59
http://reply.papertrans.cn/23/2283/228259/228259_4.png
昏睡中
发表于 2025-3-22 10:07:47
http://reply.papertrans.cn/23/2283/228259/228259_5.png
Inscrutable
发表于 2025-3-22 15:10:37
Clinical Trials for Disease-Modifying Agents in Parkinson’s Diseaseor this. PD is clinically and pathophysiologically heterogeneous and has relatively insidious and protracted progression. Symptomatic therapies confound measurement of the disease as well. With this complexity comes the challenge of identifying optimal study design and outcome measures for clinical
Inscrutable
发表于 2025-3-22 19:05:29
Value and Methods of Pharmacovigilance in the Monitoring of Drug Safety in Parkinson’s Diseases a key role in evaluating drug safety and efficacy under real-world conditions of use following market authorization. Pharmacovigilance focuses mainly on adverse drug reactions (ADRs), which are unintended adverse medical events caused by an approved drug used at normal human doses for the prophyla
inscribe
发表于 2025-3-22 22:11:13
http://reply.papertrans.cn/23/2283/228259/228259_8.png
Prognosis
发表于 2025-3-23 04:52:04
http://reply.papertrans.cn/23/2283/228259/228259_9.png
Glutinous
发表于 2025-3-23 05:51:40
http://reply.papertrans.cn/23/2283/228259/228259_10.png